Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256081 | 0.89 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14ALDH1A1 | |
| SCHEMBL15130512 | 0.85 | HDAC6 (0.45) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL10260946 | 0.85 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL21880331 | 0.85 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL381146 | 0.84 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL8383402 | 0.82 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14PDK2 | |
| Succinic Acid SCHEMBL28315096 | 0.82 | PHF8 (0.39) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL8383405 | 0.82 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL23138243 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14PDK2 | |
| SCHEMBL3293559 | 0.82 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2018071606-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9809591-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3190108-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9670183-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| EP-2683244-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES INC (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2012068440-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753418-B2 | Compounds for the modulation of Myc activity | MYC, MYCBP, MYCBP2 | HDAC6 2305/4885HDAC1 1771/4885HDAC2 4098/4885 |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | HDAC6 796/4885HDAC1 797/4885HDAC2 1117/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HDAC6 1544/4885HDAC1 1320/4885HDAC2 2632/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HDAC6 1547/4885HDAC1 1306/4885HDAC2 2641/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | HDAC6 3714/4885HDAC1 4468/4885HDAC2 3246/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | HDAC6 3714/4885HDAC1 4468/4885HDAC2 3246/4885 |
| US-20230061891-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | HDAC6 674/4885HDAC1 43/4885HDAC2 163/4885 |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | HDAC6 3556/4885HDAC1 4508/4885HDAC2 3086/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HDAC6 694/4885HDAC1 264/4885HDAC2 542/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HDAC6 18/4885HDAC1 199/4885HDAC2 490/4885 |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | HDAC6 1650/4885HDAC1 1704/4885HDAC2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.